Highest-materiality recent filing
Cibus appoints Craig Wichner as CEO; Peter Beetham returns to President/COO
Craig Wichner appointed CEO effective June 8, 2026; previously board member since Nov 2025.
Cibus stockholders elect nine directors and ratify auditor at 2026 annual meeting
All nine board nominees (Mark Finn, Peter Beetham, Kimberly A. Box, Jean-Pierre Lehmann, August Moretti, Gerhard Prante, Rory Riggs, Thomas Urban, Craig Wichner) were elected with substantial support.
Cibus Q1 net loss narrows to $21.2M; Rice HT U.S. launch pushed to 2029
Net loss of $21.2M ($0.33/share) vs $49.4M ($1.34) in Q1 2025; no goodwill impairment this quarter.
Cibus appoints Thomas Urban to board of directors
Appointed Thomas Urban, founder of Agribusiness Advisors, effective April 7, 2026.
Cibus raises ~$13.5M in public offering of 6.98M shares at $2.15/share
Underwritten public offering of 6,976,744 shares of Class A common stock at $2.15 per share.
Cibus Q4 loss $31.9M; cash $9.9M; Jan 2026 offering $22.3M; exploring strategic alternatives
Cash and equivalents $9.9M at Dec 31, 2025; with $19.8M net Jan 2026 offering, runway into late Q3 2026.
Cibus announces public offering of 13.3M shares at $1.50; board members buy 1M shares
Offering of 13,333,333 shares of Class A common stock at $1.50 per share; BTIG sole underwriter.
Cibus Updates Business Outlook in 8-K, Projects >$200M Annual Royalties from Rice Traits
Cibus estimates over $200 million potential annual addressable royalties from Rice herbicide tolerance traits in the US and Latin America.
Cibus purchases 60,088 shares from employee Anthony Moran at $0.0001/share
Purchased 60,088 shares of Class A common stock from employee Anthony Moran at $0.0001 per share.
Cibus Q3 net loss $24.3M; $23.9M cash; signs 7 Rice customers
Net loss $24.3M ($0.44/share) vs $201.5M year-ago which included $181.4M goodwill impairment.
Cibus appoints Craig Wichner to Board of Directors effective Nov 5, 2025
Appointed Craig Wichner as Board member effective November 5, 2025; also serves on Strategy Committee.
Cibus appoints Carlo Broos as permanent CFO; base salary €440,000
Broos served as Interim CFO since Oct 1, 2024; previously SVP of Finance.
Kimberly A. Box, 65, appointed to board effective September 11, 2025.
Cibus Q2 net loss narrows to $26.6M; cash runway into Q2 2026; Rice trait commercialization on track
Net loss $26.6M ($0.61 per share) vs $28.5M ($1.14) YoY; R&D $12.2M, SG&A $6.6M, both down on cost cuts.
Cibus cuts 34 jobs (~$0.5M severance charge) to streamline focus
Board approved reduction of approximately 34 full-time employees on July 21, 2025.
Cibus prices 15.7M-share public offering at $1.75/share; expected close June 9
Entered Securities Purchase Agreements for 15,714,285 shares at $1.75/share in registered public offering.
Cibus streamlines focus on Rice weed traits, targets $30M annual cash burn by 2026
Focusing on HT1 and HT3 herbicide tolerance traits in Rice for commercial launch in Latin America (2027-2028) and U.S. mid-south (2028).
Stockholders approve Cibus 2025 Employee Stock Purchase Plan; 326,384 shares reserved
Stockholders at May 22, 2025 annual meeting approved adoption of Cibus 2025 ESPP.
All seven director nominees elected; advisory say-on-pay passed with 13.2M votes for.
Cibus Q1 net loss $49.4M; cash $23.6M into Q3; evaluates strategic alternatives
Net loss of $49.4M ($1.34 per share) vs $27.0M a year ago; includes $21.0M non-cash goodwill impairment.
Cibus discloses $650K base salary for Interim CEO Dr. Peter Beetham
Base salary of $650,000 approved March 24, 2025, effective February 24, 2025.
Cibus Q4 2024 net loss $25.8M; cash $14.4M; reviews strategic alternatives
Q4 2024 net loss $25.8M vs $277.2M in Q4 2023 (prior-year includes $249.4M goodwill impairment); EPS -$0.87 vs -$12.59.
Cibus CEO Rory Riggs resigns; President Peter Beetham named interim CEO
Rory Riggs resigns as CEO, remains Chairman of the Board.
Cibus raises ~$22.6M in registered direct offering; CEO Riggs participates at $2.50/share
Company sells 4,340,000 shares at $2.50 each with common warrants; 4,700,000 pre-funded warrants at $2.4999.
Cibus sets 2025 base salary for Carlo Broos at $320,000
Compensation Committee approved $320,000 base salary for Carlo Broos effective Dec 3, 2024.
Cibus appoints August Moretti to Board of Directors and Audit Committee effective Nov 18, 2024
August Moretti, 74, appointed as director and Audit Committee member effective November 18, 2024.
Cibus Q3 net loss $201.5M on $181.4M goodwill impairment; cash runway into late Q1 2025
Net loss $201.5M ($7.63/sh) vs $34.5M ($1.59/sh) YoY; includes $181.4M non-cash goodwill impairment.
Cibus files updated corporate presentation with no material changes
Company furnished an updated corporate presentation dated October 2024.
Cibus cuts ~26 jobs, initiates cost reduction actions; expects $0.35M in Q4 charges
Workforce reduction of ~26 full-time employees approved Oct 16, communicated Oct 18.
Cibus appoints Carlo Broos as Interim CFO effective October 1, 2024
Cornelis (Carlo) Broos appointed Interim CFO; previously SVP of Finance since 2024.
Cibus partially exercises over-allotment option, issuing 289,953 additional shares at $4.00
Representatives exercised option for 289,953 additional shares at $4.00 per share.
Cibus launches $12M underwritten public offering of 3M shares at $4.00/share
Offering of 3,000,000 shares at $4.00 per share; net proceeds ~$11.2M ($12.8M with overallotment).
Underwritten offering announced; terms not disclosed. Company cites continuing capital resource constraints.
Cibus CFO Wade King to take indefinite leave; Carlo Broos appointed interim CFO
CFO Wade King steps down effective Sept 30, 2024 for family reasons; plans indefinite leave.
Cibus reports Q2 net loss of $28.5M; cash $30M; sees runway into Q4 2024
Net loss of $28.5M ($1.14 loss per share) vs $20.5M loss in year-ago period (not comparable due to merger).
Cibus raises ~$13M in direct offering; CEO invests at $10.20/unit
Gross proceeds ~$12.98M from sale of 1,298,040 shares and warrants at $10.00 per unit; CEO purchased at $10.20 per unit.
Cibus shareholders re-elect six directors, approve executive pay and auditor at annual meeting
Rory Riggs, Peter Beetham, Mark Finn, Jean-Pierre Lehmann, Gerhard Prante, and Keith Walker re-elected as directors.
Net loss $27.0M ($1.12 per share) vs $5.4M in prior period; year-over-year not comparable due to business combination.
Cibus Q4 net loss $277M on $249M goodwill impairment; cash $32.7M
Net loss $277.2M ($12.59/share) vs $2.8M prior year, driven by $249.4M non-cash goodwill and intangible impairment.
Cibus files unaudited pro forma combined 2023 statement reflecting May 2023 merger
Pro forma combined net loss attributable to company: $295.8M; basic EPS loss $11.13 per share.
Cibus estimates $249.4M non-cash impairment charge on goodwill and IPR&D
Goodwill impairment of $150.4M and in-process R&D impairment of $99.0M for fiscal 2023.
Successfully regenerated wheat plants from single cells; milestone achieved a year ahead of schedule.
Cibus signs up to $80M ATM stock offering with Stifel; replaces prior deal with Jefferies
Aggregate offering price of up to $80M of Class A common stock via at-the-market offering.
Cibus amends Registration Rights Agreement to limit piggyback rights during shelf effectiveness
Amendment executed on Dec 27, 2023, with Cibus Global Majority-in-Interest.
Offering consisted of 2,106,723 shares at $9.00/share and pre-funded warrants for 50,000 shares at $10.57/warrant.
Cibus discloses substantial doubt about going concern, gets $5M CEO line of credit
As of Sep 30, 2023, Cibus had $31.9M cash and $25.1M current liabilities; substantial doubt about ability to continue as going concern.
Presentation used in securityholder discussions; no quantitative updates provided in the filing or exhibit.
Cibus Q3 2023 net loss $34.5M; cash runway only into early Q1 2024
Net loss of $34.5M ($1.59 per share) vs. $6.0M a year ago; R&D spend jumped to $17.5M.
Cibus reports pro forma combined net loss of $88.5M for nine months ended Sep 30, 2023
Pro forma combined net loss of $88.5M and operating loss of $71.7M for the nine months ended Sep 30, 2023.
Cibus CEO provides $5M unsecured line of credit at 12% interest
$5M line of credit from CEO Rory Riggs, available Jan 1 to Mar 1 2024, at 12% simple interest, due Jan 1 2026.
Peter Beetham, who had been serving as Interim Chief Executive Officer since February 2025, returned to his role as the Company’s President and Chief Operating Officer.
appointed Craig Wichner as the Company’s Chief Executive Officer on June 8, 2026.
Dr. Beetham resigned from the Board also effective June 8, 2026.
Mr. Wichner resigned from the Board and from the Strategy Committee of the Board.
Peter Beetham, the Company’s President and Chief Operating Officer, was appointed as Interim Chief Executive Officer
On February 24, 2025, Rory Riggs resigned as the Chief Executive Officer of Cibus, Inc.
On November 18, 2024, the Board of Directors (the “Board”) of Cibus, Inc. (the “Company”) appointed August Moretti to serve as a member of the Board, effective as of such date.
The Company's Board of Directors formally appointed Mr. Broos as the Company's Interim Chief Financial Officer, effective immediately.
Wade King's departure from the role of Chief Financial Officer.
Mr. King notified the Company on August 15, 2024 that he would be stepping down from the role of Chief Financial Officer, effective September 30, 2024.
the Company intends to appoint Carlo Broos, the Company’s Senior Vice President of Finance, to serve as Interim Chief Financial Officer.
On October 17, 2023, Jim Collins provided notice of his decision to resign, effective immediately, as a member of the Company’s board of directors and as a member of its Nominating and Corporate Governance Committee.
Max materiality 0.85 · Median 0.60 · Most common event other_material